All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The MPN Hub is an independent medical education platform, sponsored by AOP Health, GSK, Sumitomo Pharma, and supported through educational grants from Bristol Myers Squibb and Incyte. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View MPN content recommended for you

The phase II ODYSSEY trial: Momelotinib + luspatercept in TD MF

By Jen Wyatt Green

Mar 11, 2026

Learning objective: After reading this article, learners will be able to recall key efficacy and safety findings from the preliminary analysis of the phase II ODYSSEY trial of momelotinib + luspatercept in transfusion dependent myelofibrosis.

Do you know... What is the rationale for momelotinib + luspatercept as a novel combination strategy for the treatment of patients with transfusion dependent MF?

Almost 50% of patients with myelofibrosis (MF) develop transfusion-dependent (TD) anemia within one year of diagnosis. TD anemia is associated with negative health-related quality of life and survival impacts and represents an area of high unmet need. The phase II ODYSSEY trial (NCT06517875) is evaluating momelotinib + luspatercept in patients with TD MF as a novel combination strategy to reduce transfusion dependence.

We summarize key findings from the preliminary analysis of the trial, presented by Prithviraj Bose at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US.

Download

Enlarge